Angiotensin II-induced JNK activation is mediated by NAD(P)H oxidase in isolated rat pancreatic islets

Regulatory Peptides

Volumn 175, Issue 1-3, 2012, Pages 1-6

  Alves, E S ^a   Haidar, A A ^a   Quadros, C D ^a   Carvalho, D S ^a   Morgan, D ^b   Rocha, M S ^b   Curi, R ^b   Carpinelli, A R ^b   Hirata, A E ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Angiotensin II; Isolated islets; JAK STAT; MAPKs

Indexed keywords

ANGIOTENSIN II; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; STAT1 PROTEIN; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HORMONE ACTION; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RAT;

ANGIOTENSIN II; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; FEMALE; ISLETS OF LANGERHANS; JANUS KINASE 2; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NADPH OXIDASE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RATS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; VASOCONSTRICTOR AGENTS;

RATTUS; RODENTIA;

EID: 84858334934     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2012.01.003     Document Type: Article

References (38)

1. Touyz R.M., Schiffrin E.L. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 2000, 52:639-672.
2. Hunyady L., Catt K.J. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 2006, 20:953-970.
3. Rajagopal K., Lefkowitz R.J., Rockman H.A. When 7 transmembrane receptors are not G protein-coupled receptors. J Clin Invest 2005, 115:2971-2974.
4. Haendeler J., Berk B.C. Angiotensin II mediated signal transduction. Important role of tyrosine kinases. Regul Pept 2000, 95:1-7.
5. Yin G., Yan C., Berk B.C. Angiotensin II signaling pathways mediated by tyrosine kinases. Int J Biochem Cell Biol 2003, 35:780-783.
6. Mehta P.K., Griendling K.K. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007, 292:82-97.
7. Kim J., Ahn S., Rajagopal K., Lefkowitz R.J. Independent beta-arrestin2 and Gq/protein kinase Czeta pathways for ERK stimulated by angiotensin type 1A receptors in vascular smooth muscle cells converge on transactivation of the epidermal growth factor receptor. J Biol Chem 2009, 284:11953-11962.
8. Ananthakrishnan R., Hallam K., Li Q., Ramasamy R. JAK-STAT pathway in cardiac ischemic stress. Vascul Pharmacol 2005, 43:353-356.
9. Grote K., Luchtefeld M., Schieffer B. JANUS under stress-role of JAK/STAT signaling pathway in vascular diseases. Vascul Pharmacol 2005, 43:357-363.
10. Marrero M.B. Introduction to JAK/STAT signaling and the vasculature. Vascul Pharmacol 2005, 43:307-309.
11. Marrero M.B., Banes-Berceli A.K., Stern D.M., et al. Role of the JAK/STAT signaling pathway in diabetic nephropathy. Am J Physiol Renal Physiol 2006, 290:762-768.
12. Marrero M.B., Schieffer B., Li B., et al. Role of Janus kinase/signal transducer and activator of transcription and mitogen-activated protein kinase cascades in angiotensin II and platelet-derived growth factor-induced vascular smooth muscle cell proliferation. J Biol Chem 1997, 272:24684-24690.
13. Ravingerova T., Barancik M., Strniskova M. Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology. Mol Cell Biochem 2003, 247:127-138.
14. Leung P.S., De Gasparo M. Involvement of the pancreatic renin-angiotensin system in insulin resistance and the metabolic syndrome. J Cardiometab Syndr 2006, 1:197-203.
15. Lastra G., Manrique C.M., Hayden M.R. The role of beta-cell dysfunction in the cardiometabolic syndrome. J Cardiometab Syndr 2006, 1:41-46.
16. Leung K.K., Leung P.S. Effects of hyperglycemia on angiotensin II receptor type 1 expression and insulin secretion in an INS-1E pancreatic beta-cell line. JOP 2008, 9:290-299.
17. Lenzen S. Oxidative stress: the vulnerable beta-cell. Biochem Soc Trans 2008, 36:343-347.
18. Lopes J.P., Oliveira S.M., Soares F.J. Oxidative stress and its effects on insulin resistance and pancreatic beta-cells dysfunction: relationship with type 2 diabetes mellitus complications. Acta Med Port 2008, 21:293-302.
19. Robertson R.P. Beta-cell deterioration during diabetes: what's in the gun?. Trends Endocrinol Metab 2009, 20:388-393.
20. Hirata A.E., Morgan D., Oliveira-Emilio H.R., et al. Angiotensin II induces superoxide generation via NAD(P)H oxidase activation in isolated rat pancreatic islets. Regul Pept 2009, 153:1-6.
21. Lacy P.E., Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 1967, 16:35-39.
22. Kandalam U., Clark M.A. Angiotensin II activates JAK2/STAT3 pathway and induces interleukin-6 production in cultured rat brainstem astrocytes. Regul Pept 2010, 159:110-116.
23. Banes A.K., Shaw S., Jenkins J., et al. Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli. Am J Physiol Renal Physiol 2004, 286:653-659.
24. Modesti A., Bertolozzi I., Gamberi T., et al. Hyperglycemia activates JAK2 signaling pathway in human failing myocytes via angiotensin II-mediated oxidative stress. Diabetes 2005, 54:394-401.
25. Touyz R.M. Oxidative stress and vascular damage in hypertension. Curr Hypertens Rep 2000, 2:98-105.
26. Wilcox C.S. Reactive oxygen species: roles in blood pressure and kidney function. Curr Hypertens Rep 2002, 4:160-166.
27. Griendling K.K., Sorescu D., Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000, 86:494-501.
28. Morgan D., Oliveira-Emilio H.R., Keane D., et al. Glucose, palmitate and pro-inflammatory cytokines modulate production and activity of a phagocyte-like NADPH oxidase in rat pancreatic islets and a clonal beta cell line. Diabetologia 2007, 50:359-369.
29. Sakuraba H., Mizukami H., Yagihashi N., et al. Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia 2002, 45:85-96.
30. Ushio-Fukai M., Alexander R.W. Reactive oxygen species as mediators of angiogenesis signaling: role of NAD(P)H oxidase. Mol Cell Biochem 2004, 264:85-97.
31. Eguchi S., Dempsey P.J., Frank G.D., et al. Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J Biol Chem 2001, 276:7957-7962.
32. Ding L., Chapman A., Boyd R., et al. ERK activation contributes to regulation of spontaneous contractile tone via superoxide anion in isolated rat aorta of angiotensin II-induced hypertension. Am J Physiol Heart Circ Physiol 2007, 292:2997-3005.
33. Nishida M., Tanabe S., Maruyama Y., et al. G alpha 12/13- and reactive oxygen species-dependent activation of c-Jun NH2-terminal kinase and p38 mitogen-activated protein kinase by angiotensin receptor stimulation in rat neonatal cardiomyocyte. J Biol Chem 2005, 280:18434-18441.
34. Bao W., Behm D.J., Nerurkar S.S., et al. Effects of p38 MAPK inhibitor on angiotensin II-dependent hypertension, organ damage, and superoxide anion production. J Cardiovasc Pharmacol 2007, 49:362-368.
35. Monsalve M., Olmos Y. The complex biology of FOXO. Curr Drug Targets 2011, 12:1322-1350.
36. Cheng Z, White MF. Targeting Forkhead box O1 from the concept to metabolic diseases: lessons from mouse models. Antioxid Redox Signal 2011;14(4):649-61.
37. Del Guerra S., Lupi R., Marselli L., et al. Functional and molecular defects of pancreatic islets in human type 2 diabetes. Diabetes 2005, 54:727-735.
38. Glauser D.A., Schlegel W. The emerging role of FOXO transcription factors in pancreatic beta cells. J Endocrinol 2007, 197:195-207.